Possibilities of a new assessment scale for prediction of chronic liver disease “CLivD”
https://doi.org/10.31146/1682-8658-ecg-219-11-62-66
Abstract
The number of patients with chronic liver disease (CLD) is steadily increasing. According to the 2023 update published by the European Association for the Study of the Liver, liver diseases account for two million deaths annually and account for 4% of all deaths (1 in every 25 deaths worldwide). This review emphasizes the need for early detection and control of these diseases course, as a factor that improves the patient's prognosis. It is proposed to use a new scale of the CLivD indicator (Chronic Liver Disease indicator), based on the assessment of risk factors widely available in physician practice, to predict the risk of developing progressive liver disease in the general population.
About the Authors
L. B. Lazebnik
A.I. Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
S. V. Turkina
Volgograd State Medical University
Russian Federation
Russian Federation
References
1. Devarbhavi H, Asrani SK, Arab JP, et al. Global burden of liver disease: 2023 update. J Hepatol. 2023;79(2):516-537. doi: 10.1016/j.jhep.2023.03.017.
2. Hagström H, Thiele M, Roelstraete B, et al. Mortality in biopsy-proven alcohol-related liver disease: a population-based nationwide cohort study of 3453 patients. Gut. 2021; 70(1):170-179. doi: 10.1136/gutjnl-2019-320446.
3. Lebedeva-Nesevria N.А., Gordeeva S.S. Alcohol consumption as health risk factor for the population in the rf regions in the ‘before crisis’ and ‘after crisis’ periods (2017-2022). Health Risk Analysis 2023, no. 2, pp. 17-29. (In Russ.) doi: 10.21668/health.risk/2023.2.02. @@ Лебедева-Несевря Н.А., Гордеева С. С. Потребление алкоголя как фактор риска здоровью населения регионов России в «докризисный» и «кризисный» периоды (2017-2022 гг.) Анализ риска здоровью. 2023;2:17-29. doi: 10.21668/health.risk/2023.2.0.
4. Teng ML, Ng CH, Huang DQ, et al. Global incidence and prevalence of nonalcoholic fatty liver disease. Clin Mol Hepatol. 2023;29(Suppl):S32-S42. doi: 10.3350/cmh.2022.0365.
5. Adam R, Karam V, Cailliez V, et al; all the other 126 contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA). 2018 Annual Report of the European Liver Transplant Registry (ELTR) - 50-year evolution of liver transplantation. Transpl Int. 2018;31(12):1293-1317. doi: 10.1111/tri.13358.
6. Cotter TG, Charlton M. Nonalcoholic Steatohepatitis After Liver Transplantation. Liver Transpl. 2020;26(1):141-159. doi: 10.1002/lt.25657.
7. Evstifeeva S.E., Shalnova S.A., Kutsenko V.A., et al. Prevalence of non-alcoholic fatty liver disease among the working-age population: associations with socio-demographic indicators and behavioral risk factors (ESSE RF-2 data). Cardiovascular Therapy and Prevention. 2022;21(9):3356. (In Russ.) doi: 10.15829/1728-8800-2022-3356.@@ Евстифеева С.Е., Шальнова С.А., Куценко В.А., и др. Распространенность неалкогольной жировой болезни печени среди населения трудоспособного возраста: ассоциации с социально-демографическими показателями и поведенческими факторами риска (данные ЭССЕ-РФ-2). Кардиоваскулярная терапия и профилактика. 2022;21(9):3356. doi: 10.15829/1728-8800-2022-3356.
8. Younossi, Z., Anstee, Q., Marietti, M. et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 15, 11-20 (2018). doi: 10.1038/nrgastro.2017.109.
9. Chang Yoosoo, Ryu Seungho, Kim Yejin et al. Low Levels of Alcohol Consumption, Obesity, and Development of Fatty Liver With and Without Evidence of Advanced Fibrosis. Hepatology 2020;71(3): 861-873. doi: 10.1002/hep.30867.
10. Rinella M. E., Lazarus J. V., Ratziu V. et al.; NAFLD Nomenclature consensus group. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023 Jun 24. doi: 10.1097/ HEP.0000000000000520.
11. Lazebnik L. B. Steatotic liver disease - an international interpretation of the concept an “umbrella” for all diseases of the hepatic parenchyma. Experimental and Clinical Gastroenterology. 2023;216(8): 24-26. (In Russ.) doi: 10.31146/1682-8658-ecg-216-8-24-26. @@ Лазебник Л. Б. Steatotic liver disease - стеатозная болезнь печени - международная трактовка понятия «зонтика» для всех заболеваний печеночной паренхимы. Экспериментальная и клиническая гастроэнтерология. 2023;216(8): 24-26. doi: 10.31146/1682- 8658-ecg-216-8-24-26.
12. Åberg F, Helenius-Hietala J, Puukka P,et al.Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology. 2018;67(6):2141-2149. doi: 10.1002/hep.29631.
13. WHO. “Global progress report on HIV, viral hepatitis and sexually transmitted infections.” World health organization (2021).
14. Ventura-Cots M, Ballester-Ferré MP, Ravi S, Bataller R. Public health policies and alcohol-related liver disease. JHEP Rep. 2019;1(5):403-413. doi: 10.1016/j.jhepr.2019.07.009.
15. Allen AM, Lazarus JV, Younossi ZM. Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties. J Hepatol. 2023;79(1):209-217. doi: 10.1016/j.jhep.2023.01.026.
16. Åberg F, Luukkonen PK, But A, et al. Development and validation of a model to predict incident chronic liver disease in the general population: The CLivD score. Journal of Hepatology. 2022;77(2):302-311. DOI: 10.1016/j.jhep.2022.02.021.
17. Armstrong MJ, Schmidt-Martin D, Rowe IA, Newsome PN. Caution in Using Non-Invasive Scoring Systems in NAFLD Beyond Highly Selected Study Populations. Am J Gastroenterol. 2017;112(4):653-654. doi: 10.1038/ajg.2017.28.
18. Thiele M, Madsen BS, Hansen JF, et al. Accuracy of the Enhanced Liver Fibrosis Test vs FibroTest, Elastography, and Indirect Markers in Detection of Advanced Fibrosis in Patients With Alcoholic Liver Disease. Gastroenterology. 2018;154(5):1369-1379. doi: 10.1053/j.gastro.2018.01.005.
19. Åberg F, Färkkilä M. Drinking and Obesity: Alcoholic Liver Disease/Nonalcoholic Fatty Liver Disease Interactions. Semin Liver Dis. 2020;40(2):154-162. doi: 10.1055/s-0040-1701443.
Review
For citations:
Lazebnik L.B., Turkina S.V. Possibilities of a new assessment scale for prediction of chronic liver disease “CLivD”. Experimental and Clinical Gastroenterology. 2023;(11):62-66. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-219-11-62-66
Views:
199
Email this article 